ImmunityBio Inc. (NASDAQ:IBRX) saw a downside of -7.96% to close Monday at $1.85 after subtracting -$0.16 on the day. The 5-day average trading volume is 3,366,960 shares of the company’s common stock. It has gained $2.19 in the past week and touched a new high 3 times within the past 5 days. An average of 2,664,690 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,633,852.
IBRX’s 1-month performance is -31.99% or -$0.87 on its low of $1.84 reached on 08/02/23. The company’s shares have touched a 52-week low of $1.21 and high of $7.80, with the stock’s rally to the 52-week high happening on 05/09/23. YTD, IBRX has lost -63.51% or -$3.22 and has reached a new high 4 times. However, the current price is down -76.28% from the 52-week high price.
Valuation Metrics
IBRX stock has a beta of 1.36. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1461.59.
ImmunityBio Inc.’s quick ratio for the period ended December 30 was 0.20, with the current ratio over the same period at 0.20. The trailing 12-month EBITDA margin is -136010.42%. The firm’s gross profit as reported stood at $351.54 million against revenue of $0.24 million.
Earnings Surprise
For the quarterly period ending December 30 this year, ImmunityBio Inc.’s cash and short-term investments amounted to $2.79 million against total debt of $766.73 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 11.61% to -$116.34 million, while revenue of -$108.22 million was 6.98% off the previous quarter. Analysts expected IBRX to announce -$0.22 per share in earnings in its latest quarter, but it posted -$0.27, representing a -22.70% surprise. EBITDA for the quarter stood at more than -$95.36 million. IBRX stock balance sheet for the quarter ending December 30 shows that total liabilities totaled 875.12 million, with total debt at $766.73 million. Shareholders hold equity totaling $435.99 million.
Let’s look briefly at ImmunityBio Inc. (IBRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 25.22% to suggest the stock is trending oversold, with historical volatility in this time period at 57.45%.
The stock’s 5-day moving average is $1.99, reflecting a -15.91% or -$0.35 change from its current price. IBRX is currently trading -30.45% above its 20-day SMA, +30.28% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -27.73% and SMA200 by-64.49%.
Stochastic %K and %D was 10.48% and 11.01% and the average true range (ATR) pointed at 0.21. The RSI (14) points at 30.77%, while the 14-day stochastic is at 1.00% with the period’s ATR at 0.22. The stock’s 9-day MACD Oscillator is pointing at -0.14 and -0.38 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for ImmunityBio Inc. (NASDAQ: IBRX), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for IBRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate IBRX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is IBRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $5.00, with their median price target at $4.50. Looking at these predictions, the average price target given by analysts is for ImmunityBio Inc. (IBRX) stock is $4.50.
